MyMD Pharmaceuticals Stock Forecast, Price & News

-0.15 (-2.60 %)
(As of 06/22/2021 12:00 AM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume383,750 shs
Average Volume451,147 shs
Market Capitalization$206.90 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MYMD News and Ratings via Email

Sign-up to receive the latest news and ratings for MyMD Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About MyMD Pharmaceuticals

MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the development of drug products in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety, and sleep disorders. It commercializes MYMD-1, a novel therapeutic to impact conditions related to immunometabolic dysregulation; and SUPERA-1R, a synthetic cannabidiol that offers bioavailability and potency than botanicals. The company was incorporated in 2014 and is based in Tampa, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.00 out of 5 stars

Medical Sector

1929th out of 2,105 stocks

Diagnostic Substances Industry

32nd out of 35 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

MyMD Pharmaceuticals (NASDAQ:MYMD) Frequently Asked Questions

What stocks does MarketBeat like better than MyMD Pharmaceuticals?

Wall Street analysts have given MyMD Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MyMD Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MyMD Pharmaceuticals' next earnings date?

MyMD Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, June 25th 2021.
View our earnings forecast for MyMD Pharmaceuticals

Who are MyMD Pharmaceuticals' key executives?

MyMD Pharmaceuticals' management team includes the following people:
  • Mr. Joshua N. Silverman, Exec. Chairman (Age 51)
  • Mr. Christopher C. Schreiber, Pres, CEO & Director (Age 56)
  • Dr. Christopher C. Chapman Jr., Pres & Chief Medical Officer (Age 68)
  • Mr. Paul Rivard Esq., VP of Operations & Gen. Counsel
  • Dr. Adam Kaplin M.D., Ph.D., Chief Scientific Officer (Age 54)

Who are some of MyMD Pharmaceuticals' key competitors?

What is MyMD Pharmaceuticals' stock symbol?

MyMD Pharmaceuticals trades on the NASDAQ under the ticker symbol "MYMD."

How do I buy shares of MyMD Pharmaceuticals?

Shares of MYMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MyMD Pharmaceuticals' stock price today?

One share of MYMD stock can currently be purchased for approximately $5.61.

How much money does MyMD Pharmaceuticals make?

MyMD Pharmaceuticals has a market capitalization of $206.90 million and generates $1.58 million in revenue each year.

How many employees does MyMD Pharmaceuticals have?

MyMD Pharmaceuticals employs 6 workers across the globe.

What is MyMD Pharmaceuticals' official website?

The official website for MyMD Pharmaceuticals is

Where are MyMD Pharmaceuticals' headquarters?

MyMD Pharmaceuticals is headquartered at 855 N. WOLFE STREET, BALTIMORE MD, 21205.

How can I contact MyMD Pharmaceuticals?

MyMD Pharmaceuticals' mailing address is 855 N. WOLFE STREET, BALTIMORE MD, 21205. The company can be reached via phone at (813) 864-2566 or via email at [email protected]

This page was last updated on 6/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.